Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve the audited financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd has informed BSE that its Board of Directors will meet on Friday, May 30, 2025, at the corporate office. The main agenda is to consider and approve the audited standalone financial results for the quarter and financial year ended March 31, 2025. The company may also discuss any other matter with the chairman's permission. The trading window for dealing in the company's securities has been closed from April 1, 2025, until 48 hours after the results are publicly announced on May 30, 2025, covering directors, KMPs, promoters, and designated persons.
No immediate impact on shareholders as this is a routine pre-results intimation. Investors should watch for the audited FY25 results announcement on May 30, 2025, which will reveal the company's full-year financial performance.